Literature DB >> 23180209

The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review.

A A P Slesser1, P Georgiou, G Brown, S Mudan, R Goldin, P Tekkis.   

Abstract

Forty to fifty percent of colorectal cancer (CRC) patients develop colorectal liver metastases (CLM) that are either synchronous or metachronous in presentation. Clarifying whether there is a biological difference between the two groups of liver metastases or their primaries could have important clinical implications. A systematic review was performed using the following resources: MEDLINE from PubMed (1950 to present), Embase, Cochrane and the Web of Knowledge. Thirty-one articles met the inclusion criteria. The review demonstrated that the majority of studies found differences in molecular marker expression between colorectal liver metastases and their respective primaries in both the synchronous and metachronous groups. Studies investigating genetic aberrations demonstrated that the majority of changes in the primary tumour were 'maintained' in the colorectal liver metastases. A limited number of studies compared the primary tumours of the synchronous and metachronous groups and generally demonstrated no differences in marker expression. Although there were conflicting results, the colorectal liver metastases in the synchronous and metachronous groups demonstrated some differences in keeping with a more aggressive tumour subtype in the synchronous group. This review suggests that biological differences may exist between the liver metastases of the synchronous and metachronous groups. Whether there are biological differences between the primaries of the synchronous and metachronous groups remains undetermined due to the limited number of studies available. Future research is required to determine whether differences exist between the two groups and should include comparisons of the primary tumours.

Entities:  

Mesh:

Year:  2012        PMID: 23180209     DOI: 10.1007/s10585-012-9551-8

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  54 in total

1.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Int J Surg       Date:  2010-02-18       Impact factor: 6.071

2.  Incidence of synchronous liver metastases in patients with colorectal cancer in relationship to clinico-pathologic characteristics. Results of a German prospective multicentre observational study.

Authors:  R Mantke; U Schmidt; S Wolff; R Kube; H Lippert
Journal:  Eur J Surg Oncol       Date:  2011-12-29       Impact factor: 4.424

3.  Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.

Authors:  Joseph Kim; Hiroya Takeuchi; Stella T Lam; Roderick R Turner; He-Jing Wang; Christine Kuo; Leland Foshag; Anton J Bilchik; Dave S B Hoon
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

4.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

Authors:  Scott L Carter; Aron C Eklund; Isaac S Kohane; Lyndsay N Harris; Zoltan Szallasi
Journal:  Nat Genet       Date:  2006-08-20       Impact factor: 38.330

5.  Cancer cell morphology at the invasive front and expression of cell adhesion-related carbohydrate in the primary lesion of patients with colorectal carcinoma with liver metastasis.

Authors:  M Ono; M Sakamoto; Y Ino; Y Moriya; K Sugihara; T Muto; S Hirohashi
Journal:  Cancer       Date:  1996-09-15       Impact factor: 6.860

6.  Tumor doubling time and local immune response to hepatic metastases from colorectal cancer.

Authors:  Ayako Kito; Kuniya Tanaka; Haruka Fujimaki; Masatoshi Nakazawa; Shinji Togo; Mutsuhiko Minami; Hiroshi Shimada
Journal:  J Surg Oncol       Date:  2007-11-01       Impact factor: 3.454

7.  Cyclin A correlates with carcinogenesis and metastasis, and p27(kip1) correlates with lymphatic invasion, in colorectal neoplasms.

Authors:  Jia-Qing Li; Hiroshi Miki; Fei Wu; Kousuke Saoo; Mikio Nishioka; Masaki Ohmori; Katsumi Imaida
Journal:  Hum Pathol       Date:  2002-10       Impact factor: 3.466

8.  Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.

Authors:  Hirotoshi Kobayashi; Kenichi Sugihara; Hiroyuki Uetake; Tetsuro Higuchi; Masamichi Yasuno; Masayuki Enomoto; Satoru Iida; Mizutomo Azuma; Ryutaro Mori; Akiko Omori; Heinz-Josef Lenz; Kathleen D Danenberg; Peter V Danenberg
Journal:  Int J Oncol       Date:  2008-12       Impact factor: 5.650

9.  Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases.

Authors:  Hidekazu Kuramochi; Go Nakajima; Yuka Kaneko; Ayako Nakamura; Yuji Inoue; Masakazu Yamamoto; Kazuhiko Hayashi
Journal:  BMC Cancer       Date:  2012-03-13       Impact factor: 4.430

10.  Colorectal liver metastases.

Authors:  Ashraf J Haddad; Murad Bani Hani; Timothy M Pawlik; Steven C Cunningham
Journal:  Int J Surg Oncol       Date:  2011-06-06
View more
  19 in total

1.  Pattern and Dynamics of Distant Metastases in Metastatic Colorectal Cancer.

Authors:  Julian Walter Holch; Maximilian Demmer; Charlotte Lamersdorf; Marlies Michl; Christoph Schulz; Jobst Christian von Einem; Dominik Paul Modest; Volker Heinemann
Journal:  Visc Med       Date:  2017-02-07

2.  Growth pattern of colorectal liver metastasis as a marker of recurrence risk.

Authors:  R L Eefsen; P B Vermeulen; I J Christensen; O D Laerum; M B Mogensen; H C Rolff; G G Van den Eynden; G Høyer-Hansen; K Osterlind; B Vainer; M Illemann
Journal:  Clin Exp Metastasis       Date:  2015-03-31       Impact factor: 5.150

3.  Survival analysis and prognostic factors of palliative radiotherapy in patients with metastatic colorectal cancer: a propensity score analysis.

Authors:  Li Ba; Qingrui Wang; Haihong Wang; Lisheng Zhu; Tao Zhang; Jinghua Ren; Zhenyu Lin
Journal:  J Gastrointest Oncol       Date:  2021-10

Review 4.  Natural history of hepatic metastases from colorectal cancer--pathobiological pathways with clinical significance.

Authors:  Konstantinos A Paschos; Ali W Majeed; Nigel C Bird
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

Review 5.  Hepatic metastasis from colorectal cancer.

Authors:  Alfred Wei Chieh Kow
Journal:  J Gastrointest Oncol       Date:  2019-12

6.  Repeating of local therapy of distant metastases increases overall survival in patients with synchronous metastasized rectal cancer-a monocentric analysis.

Authors:  Marlen Haderlein; Sebastian Lettmaier; Melanie Langheinrich; Axel Schmid; Sabine Semrau; Markus Hecht; Michael Beck; Daniela Schmidt; Robert Grützmann; Rainer Fietkau; Axel Denz
Journal:  Int J Colorectal Dis       Date:  2018-07-02       Impact factor: 2.571

7.  Survival of patients with KRAS wild-type metastatic colorectal cancer is identical after sequential treatment with cetuximab and bevacizumab regardless of the sequence - A retrospective single-center study.

Authors:  Yanhong Deng; Yue Cai; Jiayu Lin; Ling Jiang; Huabin Hu
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-10-13

8.  Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal Cancer.

Authors:  M Stutz; A Mamo; D Valenti; A Hausvater; T Cabrera; P Metrakos; P Chaudhury; G Steacy; E Garoufalis; P Kavan
Journal:  Gastroenterol Res Pract       Date:  2015-02-26       Impact factor: 2.260

9.  Synchronous bone metastasis in lung cancer: retrospective study of a single center of 15,716 patients from Tianjin, China.

Authors:  Xu Guo; Wenjuan Ma; Haixiao Wu; Yao Xu; Dezheng Wang; Shuang Zhang; Zheng Liu; Vladimir P Chekhonin; Karl Peltzer; Jin Zhang; Xin Wang; Chao Zhang
Journal:  BMC Cancer       Date:  2021-05-26       Impact factor: 4.430

10.  Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial.

Authors:  C Giessen; L Fischer von Weikersthal; R P Laubender; S Stintzing; D P Modest; A Schalhorn; C Schulz; V Heinemann
Journal:  Br J Cancer       Date:  2013-08-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.